112P Macrophage inhibitory cytokine-1 as a biomarker for diagnosis and prognosis of stage I-II non-small cell lung cancer

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death and has a poor prognosis. Biomarkers should be established to improve patient care especially in early-stage NSCLC. The macrophage inhibitory cytokine-1 (MIC-1) can promote tumor invasiveness and metastasis. Therefore, our aim was to delineate the diagnostic and prognostic value of serum MIC-1 in patients with early-stage NSCLC. A total of 152 consecutive patients with stage I–II NSCLC were retrospectively reviewed and underwent follow up after total resection of tumor. Serum MIC-1 level was evaluated in patients and 229 healthy controls, and was correlated with clinical features and prognosis of patients. The level of MIC-1 of NSCLC patients was significantly higher than that of controls (P < 0.001). A threshold of 1000 pg/ml could be used to diagnose early-stage NSCLC with 96.5% specificity and 71.3% sensitivity (area under curve, 0.912; 95% CI, 0.886–0.939). Higher level of MIC-1 was associated with elder age (> 60 years old) at diagnosis (P = 0.001) and female gender (P = 0.03). There was a significant difference between the overall survival for patients with high level of MIC-1 (≥1000 pg/ml) and low level of MIC-1(log rank, P = 0.045). The overall 3-year survival rate in patients with high level of MIC-1 was significantly lower than that of patients with low MIC-1 level (84.0% vs. 97.8%, P < 0.05). Cox regression revealed that a high level of MIC-1 was a potential risk factor (HR = 7.848, 95%CI, 1.044–58.979) for compromised overall survival. The high level of serum MIC-1 might be served as a potential biomarker for diagnosis and poorer outcome in patients with early-stage NSCLC. The clinical significance could be evaluated in future studies with larger sample size.